A novel longitudinal rank-sum test for multiple primary endpoints in clinical trials: Applications to neurodegenerative disorders
Fuente:
arXiv
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Preprint |
| Veröffentlicht: |
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866929699834298368 |
|---|---|
| author | Xu, Xiaoming Ghosh, Dhrubajyoti Luo, Sheng |
| author_facet | Xu, Xiaoming Ghosh, Dhrubajyoti Luo, Sheng |
| contents | Neurodegenerative disorders such as Alzheimer's disease (AD) present a significant global health challenge, characterized by cognitive decline, functional impairment, and other debilitating effects. Current AD clinical trials often assess multiple longitudinal primary endpoints to comprehensively evaluate treatment efficacy. Traditional methods, however, may fail to capture global treatment effects, require larger sample sizes due to multiplicity adjustments, and may not fully exploit multivariate longitudinal data. To address these limitations, we introduce the Longitudinal Rank Sum Test (LRST), a novel nonparametric rank-based omnibus test statistic. The LRST enables a comprehensive assessment of treatment efficacy across multiple endpoints and time points without multiplicity adjustments, effectively controlling Type I error while enhancing statistical power. It offers flexibility against various data distributions encountered in AD research and maximizes the utilization of longitudinal data. Extensive simulations and real-data applications demonstrate the LRST's performance, underscoring its potential as a valuable tool in AD clinical trials. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2410_19190 |
| institution | arXiv |
| publishDate | 2024 |
| record_format | arxiv |
| spellingShingle | A novel longitudinal rank-sum test for multiple primary endpoints in clinical trials: Applications to neurodegenerative disorders Xu, Xiaoming Ghosh, Dhrubajyoti Luo, Sheng Methodology Applications Neurodegenerative disorders such as Alzheimer's disease (AD) present a significant global health challenge, characterized by cognitive decline, functional impairment, and other debilitating effects. Current AD clinical trials often assess multiple longitudinal primary endpoints to comprehensively evaluate treatment efficacy. Traditional methods, however, may fail to capture global treatment effects, require larger sample sizes due to multiplicity adjustments, and may not fully exploit multivariate longitudinal data. To address these limitations, we introduce the Longitudinal Rank Sum Test (LRST), a novel nonparametric rank-based omnibus test statistic. The LRST enables a comprehensive assessment of treatment efficacy across multiple endpoints and time points without multiplicity adjustments, effectively controlling Type I error while enhancing statistical power. It offers flexibility against various data distributions encountered in AD research and maximizes the utilization of longitudinal data. Extensive simulations and real-data applications demonstrate the LRST's performance, underscoring its potential as a valuable tool in AD clinical trials. |
| title | A novel longitudinal rank-sum test for multiple primary endpoints in clinical trials: Applications to neurodegenerative disorders |
| topic | Methodology Applications |
| url | https://arxiv.org/abs/2410.19190 |